Table 1 Preoperative clinical characteristics of 155 patients with uterine sarcoma

Age (y)

51.73±11.91

50.43±8.23

45.73±10.77

49.75±8.36

62.40±1.48

49.27±48.50

Gravidity

3.40±1.72

3.25±1.48

3.46±1.67

3.44±2.06

4.00±1.22

3.36±3.00

Parity

2.00±1.31

2.06±0.95

1.80±0.98

1.81±0.91

2.80±1.48

2.03±2.00

Size(mm)

58.07±29.33

80.16±36.65

66.14±30.13

61.19±35.31

94.8±47.96

69.09±66.50

BMI (kg/m2)

23.91±3.93

23.39±3.22

22.89±2.80

22.87±3.02

24.05±2.34

23.40±23.44

Localization

 Intramural

2(13.33)

30(47.62)

33(58.93)

9(56.25)

2(40)

76(49.03)

 Subserous

2(13.33)

16(25.40)

4(7.14)

1(6.25)

1(20)

24(15.48)

 Submucous

11(73.33)

17(26.98)

19(35.83)

6(37.50)

2(40)

55(34.48)

Number of masses

 1

13(86.67)

42(66.67)

27(48.21)

6(37.50)

4(80%)

92(59.35)

 ≥2

2(13.33)

21(33.33)

29(51.79)

10(62.50)

1(20%)

63(40p.65)

Menopause

 Pre-menopausal

8(53.33)

39(61.90)

47(83.93)

9(56.25)

1(20%)

104(67.10)

 Postmenopausal

7(46.67)

24(38.10)

9(16.07)

7(43.75)

4(80%)

51(32.90)

Manifestations

 Pelvic Mass

1(6.67)

23(36.51)

15(26.79)

2(12.50)

2(40%)

43(27.74)

 AUB

6(40.00)

25(39.68)

23(41.07)

7(43.75)

0(0)

61(39.35)

 PMB

7(46.67)

8(12.70)

5(8.93)

5(31.25)

3(60%

28(18.06)

 Pain

1(6.67)

7(11.11)

13(23.21)

2(12.50)

0(0)

23(14.84)

serum marker

 CA-125 abnormality

3/12(25.00)

12/58(20.69)

10/51(19.61)

3/13(23.08)

0/5(0)

28/139(20.14)

 CA19-9 abnormality

2/12(16.67)

2/58(3.45)

2/49(4.08)

1/14(7.14)

0/5(0)

7/138(5.07)

 LDH abnormality

2/5(40.00)

12/33(36.36)

6/27(22.22)

1/6(16.67)

1/3(33.33)

22/74(29.73)

US

 Benign

10(66.67)

47(74.60)

30(53.57)

9(56.25)

3(60.00)

99(63.87)

 Degeneration

0(0)

7(11.11)

16(28.57)

1(6.25)

1(20.00)

25(16.13)

 Malignant tumors

5(33.33)

9(14.29)

10(17.86)

6(37.50)

1(20.00)

31(20.00)